Medtronic, Inc. and Scil Technology Establish Partnership for Dental Bone Regeneration Therapies

MEMPHIS, Tenn. & MARTINSREID, Germany--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) and Scil Technology GmbH today announced a development, licensing and supply agreement between Medtronic and Scil Technology. The agreement focuses on development of Scil’s biologic rhGDF-5 (recombinant human Growth and Differentiating Factor 5) dental regenerative technology for use in bone regeneration for dental implant placement and treatment of periodontal disease. Under this agreement, Scil Technology is primarily responsible for all research and development activities with Medtronic responsible for clinical trials, regulatory approvals and commercialization. Financial terms are not being disclosed.

Back to news